A New Preoperative Era in Intrahepatic Bile Duct Cancer: The GOLP Protocol
In this article
In intrahepatic cholangiocarcinoma with a high risk of recurrence, a neoadjuvant four-drug combination produced a historic leap in survival data.
Intrahepatic bile duct cancer (iCCA) is one of oncology’s quietest yet most relentlessly progressing diseases. Even among patients who can undergo surgery, the recurrence rate exceeds 50%. Until now, chemotherapy alone after surgery (capecitabine) was our guide; however, this “playing it safe” approach was insufficient for patients with high-risk factors. New England Journal of Medicine published the ZSAB-neoGOLP study on 4 March 2026, demonstrating how “taming” the tumor at the molecular level before surgery and mapping its biology could double survival.
Whom Do We Call “High Risk”?
The patients enrolled in the study had at least one of the following criteria indicating a very high likelihood of recurrence, for which the surgeon’s knife alone would not suffice:
Eligibility Criteria (High-Risk Factors)
Study Design and Treatment Arms
In this Phase 2-3, open-label, randomized, multicenter study, 178 patients were assigned in a 1:1 ratio to two main arms:
- Gemcitabine + Oxaliplatin: 3 cycles (every 3 weeks).
- Toripalimab (Anti-PD-1): 3 cycles (240 mg).
- Lenvatinib (Oral): 8 mg daily for 9 weeks.
- Surgery: Radical resection after the protocol.
- Adjuvant: 8 cycles of capecitabine.
Patients underwent immediate radical surgical resection, followed by 8 cycles of adjuvant capecitabine chemotherapy.
(Standard-of-Care Arm)
All operations were performed by hepatobiliary surgeons with at least 10 years of experience, and porta hepatis lymphadenectomy was routinely performed.
Clinical Data: Results at a Median Follow-up of 16.9 Months
At the end of a median follow-up of 16.9 months, patients who received the neoadjuvant GOLP protocol showed a striking advantage over the control group:
Event-free survival (EFS) more than doubled (18 months vs 8.7 months), reaching the highest level of statistical significance at p < 0.001. In addition, the 24-month overall survival (OS) rate was 79% in the neoadjuvant group, compared with 61% in the surgery-only group (HR: 0.43).
Pathological Success and the “R0” Goal
The four-drug combination did more than make the surgeon’s work easier; it achieved complete silence at the tissue level:
- Objective Response (ORR): Significant tumor shrinkage was observed in 55% of patients receiving GOLP.
- Major Pathological Response (MPR): Viable tumor cells fell below 10% in 19% of patients.
- Pathological Complete Response (pCR): In 5% of patients, no viable cancer cells remained on surgical pathology.
Both arms achieved very high R0 resection rates (clear surgical margins), at 93-95%. This is evidence that neoadjuvant treatment did not compromise surgical safety.
The Cost of the Journey: Safety and Side Effects
A four-drug treatment protocol can create certain sensitivities in the body’s internal balance. During the neoadjuvant phase, 26% of patients experienced grade 3 or higher adverse events, most commonly reduced neutrophil and white blood cell counts. Immune-related adverse events (rash, thyroid dysfunction) occurred in 36% of patients, but did not prevent surgical success or the feasibility of surgery.
An Era of Precise Guidance in Oncology
Our greatest aim on the healing journey with cancer is to offer patients not merely a “treatment,” but a “future.” When facing insidious diseases such as bile duct cancers, we no longer draw our swords and rush straight to the operating table. The GOLP protocol whispers this message: surgery is our strongest station, but reaching that station having broken the tumor’s resistance and gained biological control is vitally important.
This study published in NEJM is a triumph of our vision of “precise guidance.” Supporting high-risk patients before surgery with this four-drug alliance (Chemotherapy + TKI + Immunotherapy) is a historic step of restoration that halves the risk of recurrence. Healing means deciphering the body’s own code and finding the most appropriate path in the light of science.
Scientific Sources
- 1. Shi GM, et al. Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma. N Engl J Med 2026;394:983-995.
- 2. Primrose JN, et al. Adjuvant capecitabine for biliary tract cancer: the BILCAP trial. Lancet Oncol 2019.
- 3. TOPAZ-1: Durvalumab plus Gem/Cis in Advanced Biliary Tract Cancer. NEJM Evidence 2022.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.